MAPT and Alzheimer disease: It also alters metabolisms of tau/beta-amyloid. In turn, Alzheimer's disease affects systemic glucose metabolism by influencing alterations in behavior, frailty, memory disturbances, altered functions of the hypothalamus, and possibly alterations in plasma/peripheral Abeta levels.